News

Image source: The Motley Fool.

UnitedHealth Group (NYSE: UNH)Q4 2023 Earnings CallJan 12, 2024, 8:45 a.m. ET

Operator

Continue reading

Source Fool.com

After a tough 2022 and gains in 2023, it's fair to say the stock market is probably on the way to better days. In any case, history tells us that bear markets, such as the one that began in 2022

There are many ways one could end up with $1 million or more by retirement. Putting enough money in a savings account or winning the lottery are among them. However, neither of these methods can

Dividend investing is practically always in style. There is nothing quite like getting paid to own shares in a company, and for those who opt to reinvest their dividends, doing so works wonders on

Growth stocks were back in style in 2023 after a disappointing year in 2022. However, not every growth-oriented company kept pace with the broader indexes. Here are two that didn't: Sarepta

Shares of gene sequencing leader Illumina (NASDAQ: ILMN) rallied 36.6% in December, according to data from S&P Global Market Intelligence.

Investors might not be quite so excited, as Illumina

Pharmaceutical giant Pfizer (NYSE: PFE) went through a growth spurt during the COVID-19 pandemic as one of the leading vaccine companies. But the windfall of billions of extra dollars in revenue and

If you're a dividend investor with a leaning toward value investing, you'll want to do a deep dive on Medtronic (NYSE: MDT), Texas Instruments (NASDAQ: TXN), and, perhaps, even Stanley Black &amp

Pfizer (NYSE: PFE) had a disastrous 2023, with its share price collapsing by 44%. It was one of the S&P 500's worst-performing stocks last year. The company's COVID-19 revenue nosedived as the

It isn't unusual for top medical device maker Medtronic (NYSE: MDT) to score regulatory approvals for its goods. Nevertheless, in the healthcare field, nearly any regulatory win is considered a

Pharmaceutical company AbbVie (NYSE: ABBV) has been a double-deal of price growth and dividend income over the past five years. It achieved 129% in total returns in that time, outpacing the S&P 500.

Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) has delivered market-beating returns over the past 12 months, five years, and 10 years. Existing shareholders are happy, but those still on the

Income investors love high dividend yields. Unfortunately, those yields often come with unacceptable trade-offs in the form of significant risk and/or low overall growth prospects. That's not always

Investors seeking stocks that can produce dramatic gains in 2024 can find what they're looking for in the biopharmaceutical industry. Clinical-trial results that these two companies are expected to

It's never easy to make a list of the "best" of anything, much less stocks to buy. People invest in equities based on various factors that are different from one person to the next and will

Turning $1,000 into $2,400 in five years is no easy feat -- it requires a compound annual growth rate (CAGR) of 19.1%. However, both Regeneron (NASDAQ: REGN) and Moderna (NASDAQ: MRNA) have been

Abbott Laboratories (NYSE: ABT) is a longtime leader in the healthcare industry. The medical device specialist has been around for decades, delivering solid returns to its loyal shareholders

AbbVie (NYSE: ABBV) is a top pharmaceutical company with a broad mix of products in its portfolio. It also pays an attractive dividend, which yields 4% -- that's more than twice the S&P 500 average

Big pharma is facing another round of major patent expirations. Before the decade's end, Bristol Myers Squibb (BMS) will lose exclusivity for the megablockbuster blood thinner Eliquis as well as its

There are many ways to grow one's wealth over a decade, but few are as accessible as investing in stocks. Even with a relatively modest sum, picking the right investments and letting time and

Dividends are nice. But do you know what's even nicer? Fast-growing dividends. That's especially true with inflation eroding the purchasing power of your money.

The good news for income investors is

Eli Lilly (NYSE: LLY) has been one of the hottest healthcare stocks to own in recent years. The company is now the most valuable healthcare company in the world, with a valuation of around $550

Inflation is arguably the top economic story of the last couple of years. Indeed, consumer purchasing power is down 16% since the beginning of 2020. That means $1,500 would only buy $1,260 worth of

With the launch of its first gene therapy that's near-curative for sickle cell disease (SCD), everyone's talking about CRISPR Therapeutics (NASDAQ: CRSP) and its collaboration partner Vertex